10-NOV-2026 6:10

BREAST ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 1 Y 1 Tissue for MammaPrint testing 960 1279 520 238 127 42 13 11/27/2023 399 131
            1279 520 238 127 42 13      
 
    2 Y 2 SOC Chemotherapy   221 88 35 16 9 3 11/27/2023    
        3 SOC Chemotherapy + Durvalumab   217 90 33 21 9 2      
            438 178 68 37 18 5      
 
  S2212-Breast, TNBC, Neoadj Chemo + Pembro 1 Y 1 Carbo + Paclitaxel + Pembro -> AC + Pembro 2400 902 410 209 109 31 9 09/15/2023 451 163
        2 Carbo + Docetaxel + Pembro   897 403 205 104 35 7      
            1799 813 414 213 66 16      
 
Yes A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib 1 E Total Registrations   55 0 0 0 0 0 03/11/2021 464 191
            55 0 0 0 0 0      
 
  A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab 1 E Total Registrations   74 30 21 10 5 2 08/24/2023 440 185
            74 30 21 10 5 2      
 
  NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA 1 T Total Registrations   1 0 0 0 0 0 09/22/2017    
            1 0 0 0 0 0      
 
  NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 1 T Total Registrations   7 0 0 0 0 0 06/22/2018    
            7 0 0 0 0 0      
 
No A012303-Breast, HER2+, Shortened Adj 1 E Total Registrations   8 8 5 3 3 0 03/06/2026 88 36
            8 8 5 3 3 0      
 
  NRGBR009-Breast, EarlyStg, Adjuvant Chemo 1 E Total Registrations   72 44 23 15 4 3 01/31/2024 521 197
            72 44 23 15 4 3      
 
    2 E Total Registrations   51 27 10 7 1 0 01/31/2024    
            51 27 10 7 1 0      
 

10-NOV-2026 6:10

BREAST Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2511 Brst, de novo StgIV oligo, locoreg tx vs SOC 1 Initial Registration 18-Aug-26 122 33
  2 Cohort Assignment/Randomization 18-Aug-26 122 33